CA3038526A1 - Immunomodulatory fusion proteins - Google Patents

Immunomodulatory fusion proteins Download PDF

Info

Publication number
CA3038526A1
CA3038526A1 CA3038526A CA3038526A CA3038526A1 CA 3038526 A1 CA3038526 A1 CA 3038526A1 CA 3038526 A CA3038526 A CA 3038526A CA 3038526 A CA3038526 A CA 3038526A CA 3038526 A1 CA3038526 A1 CA 3038526A1
Authority
CA
Canada
Prior art keywords
seq
fusion protein
cancer
expression vector
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3038526A
Other languages
English (en)
French (fr)
Inventor
Christopher Larson
Tony Reid
Bryan T. Oronsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epicentrx Inc
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Publication of CA3038526A1 publication Critical patent/CA3038526A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
CA3038526A 2016-09-27 2017-09-27 Immunomodulatory fusion proteins Pending CA3038526A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662400338P 2016-09-27 2016-09-27
US62/400,338 2016-09-27
US201762484841P 2017-04-12 2017-04-12
US62/484,841 2017-04-12
PCT/US2017/053765 WO2018064190A1 (en) 2016-09-27 2017-09-27 Immunomodulatory fusion proteins

Publications (1)

Publication Number Publication Date
CA3038526A1 true CA3038526A1 (en) 2018-04-05

Family

ID=61763625

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3038526A Pending CA3038526A1 (en) 2016-09-27 2017-09-27 Immunomodulatory fusion proteins

Country Status (11)

Country Link
US (3) US10906957B2 (OSRAM)
EP (1) EP3519442A4 (OSRAM)
JP (2) JP7421338B2 (OSRAM)
KR (2) KR20240014617A (OSRAM)
CN (2) CN118307682A (OSRAM)
AU (1) AU2017336546C1 (OSRAM)
BR (1) BR112019005964A2 (OSRAM)
CA (1) CA3038526A1 (OSRAM)
IL (1) IL265657A (OSRAM)
MX (1) MX2019003445A (OSRAM)
WO (1) WO2018064190A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
BR112018008865A8 (pt) 2015-11-02 2019-02-26 Five Prime Therapeutics Inc polipeptídeos do domínio extracelular cd80 e seu uso no tratamento do câncer
CA3038526A1 (en) 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
AU2018254542B2 (en) 2017-04-21 2022-12-22 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
MX2019012849A (es) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
EP3628049B1 (en) 2017-05-04 2023-05-10 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
EP3684419A1 (en) * 2017-09-19 2020-07-29 Paul Scherrer Institut Transglutaminase conjugation method and linker
CA3077223A1 (en) 2017-09-27 2019-04-04 Epicentrx, Inc. Immunomodulatory fusion proteins
EP3810172A4 (en) 2018-06-21 2022-04-20 Shattuck Labs, Inc. Heterodimeric proteins and uses thereof
TW202019959A (zh) * 2018-06-22 2020-06-01 德商馬克專利公司 用於治療膽道癌的標靶性tgf-b抑制之給藥方案
CN120775065A (zh) 2018-07-09 2025-10-14 普瑞赛格恩公司 融合构建体及其使用方法
EP3870601A4 (en) * 2018-10-25 2022-07-13 Kindred Biosciences, Inc. IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
AU2020276296A1 (en) * 2019-05-16 2021-11-11 Shattuck Labs, Inc. NK cell-directed chimeric proteins
CN114466657B (zh) * 2019-07-25 2024-11-15 芝加哥大学 包括蛋白酶激活治疗剂的组合物和方法
CN112574314A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 一种融合蛋白及其应用
CN111000982A (zh) * 2019-12-25 2020-04-14 沣潮医药科技（上海）有限公司 Amhr2重组蛋白或融合蛋白在制备amh信号轴异常活化相关疾病治疗药物中的用途
CN111154806A (zh) * 2020-01-08 2020-05-15 深圳普菲科生命科技有限公司 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
EP4097219A4 (en) * 2020-01-28 2023-10-11 ImmunityBio, Inc. CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORS
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
KR20230024252A (ko) * 2020-03-23 2023-02-20 자임워크스 비씨 인코포레이티드 차폐된 il12 융합 단백질 및 이의 사용 방법
CN111690070A (zh) * 2020-05-13 2020-09-22 深圳市众循精准医学研究院 一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
GB2621482B (en) 2020-05-13 2024-09-04 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
CN113913379B (zh) * 2020-07-07 2024-02-06 深圳市菲鹏生物治疗股份有限公司 T淋巴细胞及其应用
WO2022011256A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
KR20230048046A (ko) * 2020-08-12 2023-04-10 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 감마 델타 t 세포를 자극하기 위한 방법 및 조성물
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
IL302017A (en) 2020-10-25 2023-06-01 Araris Biotech Ag Means and methods for creating antibody-linker conjugates
CN112375149B (zh) * 2020-10-30 2023-04-18 沣潮医药科技（上海）有限公司 Ace2免疫融合蛋白及其应用
WO2022105751A1 (zh) * 2020-11-19 2022-05-27 信达生物制药(苏州)有限公司 TGFβRII融合蛋白以及其用途
WO2024158813A2 (en) * 2023-01-24 2024-08-02 Providence Health & Services - Oregon Pet tracer for detection of transforming growth factor beta
CN118580372A (zh) * 2023-03-01 2024-09-03 广东菲鹏制药股份有限公司 靶向TGFβ的融合蛋白及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US5998598A (en) * 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
KR20010006534A (ko) 1997-04-18 2001-01-26 아스트루 마이클 제이 Ⅱ형 ｔｇｆ-베타 수용체／면역글로불린 불변 영역 융합 단백질
WO1999065948A1 (en) 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
DE60025832T2 (de) * 1999-08-09 2006-08-31 Emd Lexigen Research Center Corp., Billerica Mehrere zytokin-antikörper komplexen
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
US20030125251A1 (en) 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
US7820793B2 (en) 2002-02-08 2010-10-26 University Of Medicine And Dentistry Of New Jersey IFN-λ polypeptides and compositions
US20070184052A1 (en) 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
WO2005024027A1 (ja) 2003-09-02 2005-03-17 National Institute Of Advanced Industrial Science And Technology 抗体医薬
WO2006070024A2 (de) 2004-12-31 2006-07-06 Per Sonne Holm E1 -minus adenoviren und deren verwendung
US20090155267A1 (en) 2005-02-09 2009-06-18 Apollo Life Sciences Limited Molecule and chimeric molecules thereof
EP1858923A4 (en) 2005-02-14 2008-10-15 Apollo Life Sciences Ltd MOLECULAR AND CHIMERAL MOLECULES FROM IT
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2012228248A (ja) * 2005-08-19 2012-11-22 Abbott Lab 二重可変ドメイン免疫グロブリン及びその使用
US20090175819A1 (en) 2005-11-15 2009-07-09 Apollo Life Sciences Limited Molecule and chimeric molecules thereof
EP3173484B1 (en) 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
JP2010529859A (ja) * 2007-06-15 2010-09-02 ジェンザイム、コーポレーション ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
US8658135B2 (en) 2008-03-19 2014-02-25 National Research Council Of Canada Antagonists of ligands and uses thereof
EP2293667A4 (en) 2008-05-27 2012-07-18 Kyowa Hakko Kirin Co Ltd INTERLEUKIN 10-RECEPTOR (IL-10R) ANTIBODY AND USE PROCESS
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
SI2403951T1 (sl) 2009-03-02 2016-04-29 The Regents Of The University Of California Tumorsko selektivni mutanti adenovirusa e1a in e1b
IL323000A (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
AU2011333738A1 (en) * 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
ES2938182T3 (es) 2012-04-30 2023-04-05 Biocon Ltd Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas
EP2970512B1 (en) 2013-03-12 2018-10-10 Biocon Limited Fusion immunomodulatory proteins and methods for making same
HK1225740A1 (zh) * 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
CN120919282A (zh) 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
AU2015213988B2 (en) 2014-02-10 2019-07-11 Merck Patent Gmbh Targeted TGFbeta inhibition
CA2966776C (en) 2014-12-19 2021-05-04 Alkermes, Inc. Single chain fc fusion proteins
KR20170138569A (ko) 2015-04-29 2017-12-15 메디오라늄 파마세우티시 에스.피.에이. 용해성 키메라 인터루킨-10 수용체 및 이의 치료학적 용도
ES3028883T3 (en) * 2015-08-31 2025-06-20 Nat Res Council Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
CA3038526A1 (en) 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
CA3077223A1 (en) 2017-09-27 2019-04-04 Epicentrx, Inc. Immunomodulatory fusion proteins

Also Published As

Publication number Publication date
CN110546168B (zh) 2024-03-15
US20180134766A1 (en) 2018-05-17
WO2018064190A1 (en) 2018-04-05
JP7421338B2 (ja) 2024-01-24
AU2017336546C1 (en) 2025-05-29
KR20240014617A (ko) 2024-02-01
AU2017336546A1 (en) 2019-05-02
CN118307682A (zh) 2024-07-09
US20250074967A1 (en) 2025-03-06
JP2019531728A (ja) 2019-11-07
BR112019005964A2 (pt) 2019-06-18
CN110546168A (zh) 2019-12-06
IL265657A (en) 2019-05-30
KR20190128618A (ko) 2019-11-18
MX2019003445A (es) 2019-09-26
EP3519442A1 (en) 2019-08-07
EP3519442A4 (en) 2020-06-17
US10906957B2 (en) 2021-02-02
US20210139560A1 (en) 2021-05-13
US12054530B2 (en) 2024-08-06
JP2024026738A (ja) 2024-02-28
AU2017336546B2 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
US20250074967A1 (en) Immunomodulatory fusion proteins
JP7702445B2 (ja) 免疫調節融合タンパク質
JP2019047828A (ja) 一本鎖Ｆｃ融合タンパク質
US12036247B2 (en) Multiple transgene recombinant adenovirus
US20190352616A1 (en) Multiple transgene recombinant adenovirus
CA3064892A1 (en) Anti-angiogenic adenovirus
KR20240099287A (ko) 이종이량체 Fc 시토카인 및 그의 용도
CN112574315B (zh) 改变效应功能的Fc变体及其融合蛋白
EA045432B1 (ru) Иммуномодулирующие слитые белки
BR122024009021A2 (pt) Proteínas de fusão imunomoduladoras, seu uso e seu método de produção, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e método para expressar uma proteína de fusão em uma célula-alvo
EA043690B1 (ru) Иммуномодулирующие слитые белки
CN118339177A (zh) 白介素-10突变蛋白及其融合蛋白

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220913

EEER Examination request

Effective date: 20220913

EEER Examination request

Effective date: 20220913

EEER Examination request

Effective date: 20220913